oral apelin receptor GPCR agonist

completed Ph. I for heart failure, discontinued

from cell-based HTS and opt.

J. Med. Chem., Mar. 19, 2021

Bristol Myers Squibb, Princeton, NJ

The Bristol Myers Squibb apelin receptor (APJ) GPCR agonist (“compound 14”) is a clinical candidate for heart failure which completed a Ph. I study. Endogenous pyroglutamated apelin-13 peptide has…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.